When a merger or acquisition (M&A) is announced, the target company’s stock price usually jumps. Over time, the combined company’s stock also tends to rise, as mergers often lead to cost savings and better efficiency, boosting earnings and investor confidence.
Here are some publicly traded stocks’ tickers that Goldman Sachs has assigned a high chance of being acquired within the next year: Altimmune (ALT), Blueprint Medicines Corp. (BPMC), BridgeBio Pharma (BBIO), Day One Biopharmaceuticals (DAWN), Insmed Incorporated (INSM), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Madrigal Pharmaceuticals (MDGL), Maravai Lifesciences Holdings (MRVI), Sarepta Therapeutics (SRPT), TripAdvisor (TRIP).
Since 2015, 9% of the bank’s picks have been involved in M&A.
Goldman Sachs 2024 M&A Outlook report
submitted by /u/FXgram_
[link] [comments]